Risk factors for early revision after total hip arthroplasty

全髋关节置换术后早期翻修的风险因素

阅读:1

Abstract

OBJECTIVE: Revision total hip arthroplasty (THA) is associated with increased cost, morbidity, and technical challenge compared to primary THA. A better understanding of the risk factors for early revision is needed to inform strategies to optimize patient outcomes. METHODS: A total of 207,256 patients who underwent primary THA between 1997-2005 in California and New York were identified from statewide databases. Unique patient identifiers were used to identify early revision THA (<10 years from index procedure). Patient characteristics (demographics, comorbidities, insurance type, and preoperative diagnosis), community characteristics (education level, poverty, and population density), and hospital characteristics (annual THA volume, bed size, and teaching status) were evaluated using multivariable regression to determine risk factors for early revision. RESULTS: The probabilities of undergoing early aseptic revision and early septic revision were 4% and <1% at 5 years, respectively. Women were 29% less likely than men to undergo early septic revision (P < 0.001). Patients with Medicaid and Medicare were 91% and 24%, respectively, more likely to undergo early septic revision than privately insured patients (P = 0.01 and P < 0.001, respectively). Hospitals performing <200 THAs annually had a 34% increased risk of early aseptic revision compared to hospitals performing >400 THAs annually (P < 0.001). CONCLUSION: A number of identifiable factors, including younger age, Medicaid, and low hospital volume, increase the risk of undergoing early revision THA. Patient-level characteristics distinctly affect the risk of revision within 10 years, particularly if due to infection. Our findings reinforce the need for continued investigation of the predictors of early failure following THA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。